



PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



Synaptogenix Inc. Rank 32 of 446



The relative strengths and weaknesses of Synaptogenix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Synaptogenix Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Synaptogenix Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 265%, being 222% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	38,586
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,313
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,880
Other Net Income	10,561
Other Revenues	0
Property and Equipment	22
Research and Development	6,325
Selling, General and Administrative Expense	9,810

Output Variable	Value in 1000 USD
Assets	38,608
Liabilities	3,193
Expenses	16,135
Revenues	0
Stockholders Equity	35,415
Net Income	-5,574
Comprehensive Net Income	-5,574
Economic Capital Ratio	265%

